Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Bintrafusp alfa + NHS-IL12 + PDS0101 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Bintrafusp alfa | MSB0011359C|M7824 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 TGFBR2 Antibody 3 | Bintrafusp alfa is a human PD-L1 (CD274) antibody fused with transforming growth factor-beta (TGF-beta, TGFBR2) receptor II extracellular domain, which blocks two immuno-inhibitory pathways simultaneously, therefore enhances anti-tumor immunity (PMID: 29298798, PMID: 32461347). | |
NHS-IL12 | M9241|M-9241 | NHS-IL12 (M9241) is an immunocytokine composed of IL-12 linked to human tumor necrosis factor targeted IgG1, which may result in enhanced anti-tumor immune response (PMID: 24681847). | ||
PDS0101 | PDS 0101|PDS-0101 | PDS0101 is a cancer vaccine comprising 6 HPV-16 E6 and E7 peptides encapsulated in a lipid nanoparticle, which potentially stimulates anti-tumor immune response (PMID: 32554612). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04287868 | Phase Ib/II | Bintrafusp alfa + NHS-IL12 + PDS0101 | Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies | Active, not recruiting | USA | 0 |